Viatris (NASDAQ:VTRS) has officially commenced the global expansion of its cardiovascular portfolio with the launch of Inpefa (sotagliflozin) in the United Arab Emirates, marking the first commercial availability of the therapy outside the United States.
Performance Shipping (NASDAQ:PSHG) secured a three-year charter agreement with PBF Energy, pushing its revenue backlog to an all-time high and reinforcing its strategy of locking in long-term cash flow amid a volatile global energy market.
Barnes & Noble Education (NYSE:BNED) shares rose Tuesday after the campus bookstore operator reported a return to profitability for its fiscal second quarter, driven by aggressive growth in its inclusive-access course material programs.
Phio Pharmaceuticals (NASDAQ:PHIO) reported that its experimental gene-silencing therapy cleared tumors in the majority of patients during a mid-stage study, marking a significant win for its proprietary INTASYL technology.
MSC Income Fund (NYSE:MAIN) signaled a strong finish to 2025, providing preliminary fourth-quarter results that point to rising asset values and double-digit returns on equity as it navigates a stabilizing interest rate environment.
ZOOZ Strategy (NASDAQ:ZOOZ) finished 2025 with a significantly bolstered balance sheet and a clean debt profile, reflecting the company’s aggressive transition from energy storage to a Bitcoin-anchored holding company.
Corporación América Airports (NYSE:CAAP) reported robust passenger growth for 2025, fueled by a surge in international travel and record-breaking performances in key markets.
Regentis Biomaterials (NYSE:RGNT) shares gained after new long-term imaging data showed its hydrogel implant successfully regenerated knee cartilage with a structural complexity nearly identical to healthy human tissue.
Celcuity (NASDAQ:CELC) shares rose in premarket trading Tuesday after the U.S. Food and Drug Administration accepted the New Drug Application for gedatolisib, a potential first-in-class therapy for patients with advanced breast cancer.
Dyne Therapeutics (NASDAQ:DYN) secured a regulatory win in Asia as Japanese authorities granted orphan drug status to its lead candidate for myotonic dystrophy, providing the biotech with a clear path toward market exclusivity in the world’s third-largest pharmaceutical market.
AmeriServ Financial (NASDAQ:ASRV) reported a sharp rise in fourth-quarter and full-year earnings, as significantly higher net interest income outweighed a multi-million dollar charge-off linked to a troubled commercial real estate loan.
